Kiadis Pharma is a Dutch biotech company developing a modified donor T-cell infusion (ATIR) given after a stem-cell transplant to treat acute leukaemia.
More Kiadis Pharma content >Investment summary
Kiadis is developing ATIR: an allogeneic donor T-cell preparation that uses its Theralux technology to deplete alloreactive T-cells that can cause Graft vs Host disease (GvHD). The ATIR T-cell preparation is given 28-32 days after a T-cell depleted haploidentical bone marrow transplant, a protocol sometimes used to treat acute leukaemia. ATIR is in a European Phase III study against the clinically favoured ‘Baltimore’ protocol. The trial is planned to report in H2 2020. A conditional marketing application has been filed with the EMA and an opinion is likely in Q418 as 180 day questions were answered in August. Cash at 30 June 2018 was €41.7m with repayable debt of €15m. A new loan agreement for €20m has been made. Our forecasts are under review.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
---|---|---|---|---|---|---|
2016A | 0.0 | (10.8) | (12.5) | (1105.0) | N/A | N/A |
2017A | 0.0 | (14.7) | (17.2) | (1060.0) | N/A | N/A |
2018E | N/A | N/A | N/A | N/A | N/A | N/A |
2019E | N/A | N/A | N/A | N/A | N/A | N/A |
Content on Kiadis Pharma















Sector |
---|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
---|---|
Forecast net debt (€m) | N/A |
Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
*% relative to local index |
Key management |
|
---|---|
Arthur Lahr | CEO |
Robbert van Heekeren | CFO |
You may also be interested in…
- Abliva
- AlzeCure Pharma
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- Cantargia
- Carmat
- Deinove
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- IRLAB Therapeutics
- MagForce
- Medigene
- MOLOGEN
- Newron Pharmaceuticals
- Nicox
- Nuevolution
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- RhoVac
- Ryvu Therapeutics
- Scandion Oncology
- Sequana Medical
- Targovax
- Transgene
- TxCell
- Ultimovacs
- Vivesto
- Xbrane Biopharma